XGN Exagen Inc

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.

Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds the potential to guide precision management of Lupus Nephritis, addressing a critical need for rheumatologists. Additional abstracts highlight Exagen’s innovative research on novel T Cell biomarkers for Lupus and anti-RA33 autoantibodies for rheumatoid arthritis, both of which will significantly improve diagnostic sensitivity of the AVISE CTD platform.

“Exagen’s commitment to innovative research is showcased in our abstracts and validates our continued efforts to bring novel biomarkers to the forefront of rheumatologic care,” said Dr. Andrew Concoff, Chief Innovation Officer of Exagen. “We look forward to sharing our findings with the rheumatology community, with the goal of furthering patient care.”

Below is the list of accepted abstracts, with links to each:

Plenary Session in Collaboration with Johns Hopkins

Plenary Session | Presented by Andrea Fava | Abstract #1642Title: A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus NephritisSession Title: Plenary IISession Date and Time: Sunday, November 17th, 2024, from 9:00 a.m. – 9:15 a.m. ET

Novel Biomarker Development Abstracts

Poster Presentation | Presented by Vasileios Kyttaris | Abstract #1490Title: Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE TestsSession Title: SLE – Diagnosis, Manifestations, & Outcomes, Poster IISession Date and Time: Sunday, November 17th, 2024, from 10:30 a.m. – 12:30 p.m. ET

Poster Presentation | Presented by Andrew Concoff| Abstract #2233Title: Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid ArthritisSession Title: RA – Diagnosis, Manifestations, & Outcomes, Poster IIISession Date and Time: Monday, November 18th, 2024, from 10:30 a.m. – 12:30 p.m. ET

Poster Presentation | Presented by Andrew Concoff| Abstract #2232Title: Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. CohortSession Title: RA – Diagnosis, Manifestations, & Outcomes, Poster IIISession Date and Time: Monday, November 18th, 2024, from 10:30 a.m. – 12:30 p.m. ET

Clinical Evidence Reinforcing CB-CAPs Superior Performance Compared to Conventional Tests

Poster Presentation | Presented by Andrew Concoff| Abstract #0608Title: Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation CohortSession Title: SLE – Diagnosis, Manifestations, & Outcomes, Poster ISession Date and Time: Saturday, November 16th, 2024, from 10:30 a.m. – 12:30 p.m. ET

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow @ExagenInc on X.

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation Exagen’s goals, strategies and ambitions; potential future financial and business performance; the potential for Exagen’s research to lead to positive impacts to patients; the potential for Exagen’s research to lead to new or improved testing products; the potential utility and effectiveness of Exagen’s services and testing solutions; updates to be made to AVISE® CTD; potential shareholder value and growth and 2024 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; changes in laws and regulations related to Exagen’s regulatory requirements; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:Ryan DouglasExagen Inc.ir@exagen.com760.560.1525